Uber stock surges after Nvidia partnership announcement
DUBLIN - Theravance Biopharma, Inc. (NASDAQ:TBPH), a biopharmaceutical company with "GREAT" financial health according to InvestingPro analysis, will present new analyses of its COPD treatment YUPELRI (revefenacin) at the upcoming CHEST 2025 annual meeting in Chicago, the company announced Tuesday. The company, currently valued at $701 million, has demonstrated strong market performance with a 69% return over the past year.
Two presentations scheduled for October 21 will highlight findings from separate studies of the once-daily nebulized maintenance treatment for chronic obstructive pulmonary disease. This development comes as Theravance maintains a robust balance sheet with a current ratio of 6.7, indicating strong operational stability.
A retrospective analysis of claims data showed that patients who adhered to YUPELRI following hospital discharge experienced significantly fewer and less severe exacerbations compared to non-adherent patients. The adherent group also demonstrated significantly lower healthcare-related costs, according to the company’s statement.
Additionally, post-hoc analyses from a 52-week Phase 3 safety study indicated that patients taking YUPELRI had a significantly lower incidence of moderate-to-severe acute exacerbations compared to patients taking tiotropium, with overall less severe exacerbations.
"The findings demonstrate that adherent patients to YUPELRI had significantly fewer exacerbations, and particularly less severe ones, compared to non-adherent patients," said Antonio Anzueto, Professor of Medicine at the University of Texas, Health San Antonio, in the press release.
YUPELRI is FDA-approved as a maintenance treatment for COPD. Theravance Biopharma has established a strategic collaboration with Viatris Inc. to develop and commercialize nebulized revefenacin products for COPD.
The American College of Chest Physicians annual meeting will take place from October 19-22, 2025. For investors seeking deeper insights into Theravance’s financial outlook and growth potential, InvestingPro offers comprehensive analysis with 13 additional exclusive ProTips and detailed metrics, including revenue growth of 24.5% in the last twelve months.
In other recent news, Theravance Biopharma reported impressive financial results for the second quarter of 2025, with earnings per share of $1.08, significantly exceeding the forecasted $0.67. The company’s revenue also surpassed expectations, reaching $26.2 million compared to the projected $15.92 million. Additionally, Theravance Biopharma completed the sale of its Trelegy royalties for $225 million and received a $7.5 million milestone payment following the approval of Yupelri in China. In analyst updates, B.Riley initiated coverage of Theravance Biopharma with a Buy rating and a $28.00 price target, while BTIG reiterated its Buy rating with a $25.00 price target. Leerink Partners raised its price target on the company to $13.00 from $10.00, maintaining a Market Perform rating. The company also reached a settlement with Cipla regarding patent litigation over YUPELRI inhalation solution. This settlement involved multiple parties and resolved disputes under the Hatch-Waxman Act. Theravance Biopharma’s recent developments indicate a strong financial position and ongoing strategic progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.